Why the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients

With the FDA’s approval of lecanemab, Eisai is set to promote it to the primary care physicians who treat most dementia patients and critics are speaking out.

Author

OUR DIGITAL PARTNERS

RELATED ARTICLES